Company facts
- Headquarters
- Parsippany, New Jersey
- Most recent report
- 8-K, filed Aug 12, 2026
- Incorporated
- Delaware
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 1054102
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company
Financials 8 of 119
News 8 of 311
Prospectuses and Registrations 8 of 36
- 424B4 Final prospectus for an offering Jan 13, 2022
- S-1/A Registration statement for an offering, amended Jan 7, 2022
- S-1/A Registration statement for an offering, amended Jan 3, 2022
- S-1 Registration statement for an offering Dec 6, 2021
- 25-NSE Notice that a security was delisted Apr 26, 2021
- S-8 Registration statement for an employee plan Jan 29, 2021
- S-8 Registration statement for an employee plan Oct 22, 2019
- S-8 POS Post-effective amendment to an employee plan registration Oct 22, 2019
Proxies 8 of 55
- DEFA14A Extra proxy material Jul 7, 2026
- DEF 14A Proxy statement for a shareholder vote Jul 7, 2026
- PREM14A Jun 25, 2026
- PRE 14A Preliminary proxy statement Jun 23, 2026
- DEFA14A Extra proxy material Sep 20, 2024
- DEF 14A Proxy statement for a shareholder vote Sep 20, 2024
- DEFA14A Extra proxy material Sep 22, 2023
- DEF 14A Proxy statement for a shareholder vote Sep 22, 2023
Ownership 8 of 405
- 4 Insider reported a trade Feb 17, 2026
- 4 Insider reported a trade Feb 4, 2026
- 4 Insider reported a trade Apr 25, 2025
- SCHEDULE 13G/A Large holder reported a passive stake, amended Feb 14, 2025
- SCHEDULE 13G/A Large holder reported a passive stake, amended Feb 14, 2025
- SC 13D/A Large holder reported an active stake, amended Oct 16, 2024
- SC 13D/A Large holder reported an active stake, amended Oct 16, 2024
- 4 Insider reported a trade Oct 15, 2024
Other 8 of 74
Everything here comes from Interpace Biosciences, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.